Ifinatamab deruxtecan by Daiichi Sankyo for Neuroendocrine Tumors: Likelihood of Approval

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Neuroendocrine Tumors.

Will MAPS Readouts Turn Around The Psychedelic Industry?

It’s been a tough summer for both the cannabis and psychedelics industries. It’s been causing investors a lot of concern. Is there hope that the

August 23, 2023

Innovative Caregiver Support Program Shines at Alzheimer’s Conference

At the Alzheimer’s Association International Conference, leading experts gathered to share breakthroughs in research and highlight the importance of innovative programs, including Florida’s groundbreaking caregiver

September 7, 2024

Study finds increase in mental health spending for children, adolescents since the beginning of pandemic

Spending on mental health services for children and adolescents has risen by more than one-quarter since the beginning of the COVID-19 pandemic, continuing to rise

October 5, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.